Form 4: Spyre Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Sandra Milligan acquired stock options for 21,980 shares of Spyre Therapeutics common stock on May 14, 2024.
Summary
- On May 14, 2024, Sandra Milligan, a director of Spyre Therapeutics, Inc. [SYRE], acquired stock options representing the right to purchase 21,980 shares of the company's common stock.
- The exercise price of these options is $39.29.
- The options vest in 36 equal monthly installments starting May 14, 2024, contingent upon continuous service with the issuer.
- The options expire on May 14, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a routine transaction (stock option grant) for a company director.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in corporate compensation.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of earliest transaction: Sandra Milligan acquired stock options. |
| 05/14/2024 | Vesting start date for the stock options. |
| 05/14/2034 | Expiration date for the stock options. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.